Hurrell, Benjamin P.
Helou, Doumet Georges
Howard, Emily
Painter, Jacob D.
Shafiei-Jahani, Pedram
Sharpe, Arlene H. http://orcid.org/0000-0002-9736-2109
Akbari, Omid http://orcid.org/0000-0002-4359-9725
Article History
Received: 26 January 2022
Accepted: 23 August 2022
First Online: 31 August 2022
Competing interests
: Authors have no competing interests to declare except for A.H.S. A.H.S. has patents/pending royalties on the PD-1 pathway from Roche and Novartis. A.H.S. is on advisory boards for Surface Oncology, Elstar, SQZ Biotechnologies, Elpiscience, Selecta, Bicara and Monopteros, GlaxoSmithKline, and Janssen. A.H.S. has received research funding from Novartis, Roche, UCB, Ipsen, Merck, and AbbVie unrelated to this project.